AR and breast carcinoma: The AR+Sox2– phenotype was not significantly associated with the immunophenotypes defined for FMCs (27), but was associated with those inspired by Nielsen et al. (28) and Cheang et al. (29) for breast cancers: there was a slight over-representation of Luminal-A cases among AR+Sox2– FMCs, while none of the triple-negative non-basal–like FMCs were AR+Sox2– (Supplementary Table 6).